Comparison of combination therapy with tamsulosin and dutasteride or finasteride in patients with benign prostatic hyperplasia: a randomized clinical trial

IF 0.5 Q4 UROLOGY & NEPHROLOGY
Abbas Basiri, Rasool Zare, Mazyar Zahir, Amir Hossein Kashi, Mahsa Zobeiry, Nasrin Borumandnia, Amir Reza Abedi, Shabnam Golshan
{"title":"Comparison of combination therapy with tamsulosin and dutasteride or finasteride in patients with benign prostatic hyperplasia: a randomized clinical trial","authors":"Abbas Basiri, Rasool Zare, Mazyar Zahir, Amir Hossein Kashi, Mahsa Zobeiry, Nasrin Borumandnia, Amir Reza Abedi, Shabnam Golshan","doi":"10.1186/s12301-024-00451-0","DOIUrl":null,"url":null,"abstract":"Based on our observations at the largest outpatient urology clinic in Iran, patients for whom finasteride is prescribed as a secondary drug to tamsulosin tend to experience earlier and more severe sexual side effects without any difference in the amelioration of symptoms. This study aimed to compare the time lag, efficacy, and side effects of combination therapy with varying doses of dutasteride or finasteride added to tamsulosin for benign prostatic hyperplasia (BPH) treatment. In this study 165 were randomized into 5 groups (each N = 33); receiving tamsulosin 0.4mg plus either of A: finasteride 3mg, B: placebo, C: dutasteride 0.25mg, D: finasteride 5mg or E: dutasteride 0.5mg. During the 6-month period of the study, International Prostate Symptom Score (IPSS), post-void residual urine (PVR), International Index of Erectile Function (IIEF-5), prostate volume (PV), prostate specific antigen (PSA) and maximum urinary flow rate (Qmax) were evaluated at baseline and at the 1st, 3rd and 6th month. The differences between each time point and baseline were then compared between groups. At 3-month follow-up, group E exhibited a higher decrease in PSA but a greater increase in Qmax compared to group A (p = 0.047 and 0.006, respectively). Group C showed higher Qmax increase compared to group A at 3 and 6 months (p = 0.003 and 0.014) and concurrently a more pronounced PV decrease at 1 and 3 months (p = 0.047 and 0.003, respectively). Group D had a significantly more decrease in their IIEF-5 compared to group A at one-month visit (p = 0.006). In summary, at the sixth-month follow-up, dutasteride demonstrated superiority over finasteride solely in enhancing Qmax. Therefore, dutasteride may be marginally more beneficial as a secondary component of combination therapy in BPH. Trial registration IRCT, IRCT20120516009772N2. Registered 18 January 2021 Retrospectively registered, https://irct.behdasht.gov.ir/search/result?query=IRCT20120516009772N2 .","PeriodicalId":7432,"journal":{"name":"African Journal of Urology","volume":"23 1","pages":""},"PeriodicalIF":0.5000,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"African Journal of Urology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s12301-024-00451-0","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Based on our observations at the largest outpatient urology clinic in Iran, patients for whom finasteride is prescribed as a secondary drug to tamsulosin tend to experience earlier and more severe sexual side effects without any difference in the amelioration of symptoms. This study aimed to compare the time lag, efficacy, and side effects of combination therapy with varying doses of dutasteride or finasteride added to tamsulosin for benign prostatic hyperplasia (BPH) treatment. In this study 165 were randomized into 5 groups (each N = 33); receiving tamsulosin 0.4mg plus either of A: finasteride 3mg, B: placebo, C: dutasteride 0.25mg, D: finasteride 5mg or E: dutasteride 0.5mg. During the 6-month period of the study, International Prostate Symptom Score (IPSS), post-void residual urine (PVR), International Index of Erectile Function (IIEF-5), prostate volume (PV), prostate specific antigen (PSA) and maximum urinary flow rate (Qmax) were evaluated at baseline and at the 1st, 3rd and 6th month. The differences between each time point and baseline were then compared between groups. At 3-month follow-up, group E exhibited a higher decrease in PSA but a greater increase in Qmax compared to group A (p = 0.047 and 0.006, respectively). Group C showed higher Qmax increase compared to group A at 3 and 6 months (p = 0.003 and 0.014) and concurrently a more pronounced PV decrease at 1 and 3 months (p = 0.047 and 0.003, respectively). Group D had a significantly more decrease in their IIEF-5 compared to group A at one-month visit (p = 0.006). In summary, at the sixth-month follow-up, dutasteride demonstrated superiority over finasteride solely in enhancing Qmax. Therefore, dutasteride may be marginally more beneficial as a secondary component of combination therapy in BPH. Trial registration IRCT, IRCT20120516009772N2. Registered 18 January 2021 Retrospectively registered, https://irct.behdasht.gov.ir/search/result?query=IRCT20120516009772N2 .
良性前列腺增生患者使用坦索罗辛、度他雄胺或非那雄胺联合疗法的比较:随机临床试验
根据我们在伊朗最大的泌尿科门诊诊所的观察,非那雄胺作为坦索罗辛的辅助用药,患者往往会更早出现更严重的性副作用,而症状的改善程度却没有任何差别。本研究旨在比较在治疗良性前列腺增生症(BPH)时,在坦索罗辛中添加不同剂量的度他雄胺或非那雄胺进行联合治疗的时滞、疗效和副作用。在这项研究中,165 人被随机分为 5 组(每组 N = 33),分别接受坦索罗辛 0.4 毫克加非那雄胺 3 毫克、B:安慰剂、C:度他雄胺 0.25 毫克、D:非那雄胺 5 毫克或 E:度他雄胺 0.5 毫克。在为期 6 个月的研究期间,分别在基线、第 1 个月、第 3 个月和第 6 个月对国际前列腺症状评分 (IPSS)、排尿后残余尿 (PVR)、国际勃起功能指数 (IIEF-5)、前列腺体积 (PV)、前列腺特异性抗原 (PSA) 和最大尿流率 (Qmax) 进行了评估。然后比较各组在每个时间点与基线之间的差异。在 3 个月的随访中,与 A 组相比,E 组的 PSA 下降幅度更大,但 Qmax 上升幅度更大(分别为 p = 0.047 和 0.006)。与 A 组相比,C 组在 3 个月和 6 个月时的 Qmax 升幅更大(p = 0.003 和 0.014),同时在 1 个月和 3 个月时的 PV 下降更明显(p = 0.047 和 0.003)。与 A 组相比,D 组患者一个月后的 IIEF-5 下降幅度更大(p = 0.006)。总之,在为期 6 个月的随访中,仅在提高 Qmax 方面,度他雄胺就优于非那雄胺。因此,作为良性前列腺增生症联合疗法的辅助成分,度他雄胺可能略胜一筹。试验注册IRCT,IRCT20120516009772N2。注册日期:2021 年 1 月 18 日 追溯注册,https://irct.behdasht.gov.ir/search/result?query=IRCT20120516009772N2 。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
African Journal of Urology
African Journal of Urology UROLOGY & NEPHROLOGY-
CiteScore
1.00
自引率
0.00%
发文量
58
审稿时长
9 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信